Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 7901–7950 of 75496
On March 13, 2025, each of Mr. Frederick Herbst and Mr. Jason Papastavrou resigned from his position as Director of the Company.
On March 13, 2025, the board of directors of the Company (the “Board”) appointed Ms. Supurna VedBrat to replace Mr. Herbst as a Class 1 Director of the Company, to serve until the Company’s annual meeting of stockholders to be held in 2025, or until her successor is duly elected and qualified.
On March 13, 2025, the board of directors of the Company (the “Board”) appointed Ms. Supurna VedBrat to replace Mr. Herbst as a Class 1 Director of the Company
On March 13, 2025, Mr. Andreas Bodmeier resigned from his position as Chief Executive Officer of the Company.
Patrick Williams has agreed to step down, effective as of the same date, at the request of the Board from his position as Chief Financial Officer.
the Board appointed Magda Michna, PhD, the Company’s Chief Clinical, Regulatory and Medical Affairs Officer, to the newly created role of Chief Development Officer
Keith Holliday, PhD has agreed to retire, effective as of the Effective Date, at the request of the Board from his position as Chief Technology Officer
Mr. Stephen C. Farrell will continue to serve as the Chief Executive Officer of the Company and as a member of the Company’s Board but, effective as of the Effective Date, will no longer hold the title of President of the Company.
the Board appointed Deborah Andrews, the Company’s former Chief Financial Officer, to serve as the Company’s Interim Chief Financial Officer and principal accounting officer on an interim basis, effective as of the Effective Date
the Board appointed the Company’s Chief Operating Officer, Warren Foust, as President and Chief Operating Officer of the Company, effective March 17, 2025
On March 16, 2025, Dr. Edward Kaye, M.D., 75, the Company’s Chief Executive Officer (“CEO”) and a director, informed the Company’s Board of Directors (the “Board”) of his intention to step down from his position as the Company’s CEO, effective March 19, 2025 (the “Transition Date”).
Also in connection with Dr. Kaye’s transition, effective as of the Transition Date, the Board appointed Arthur Tzianabos, 61, currently Chair of the Board, as Interim Executive Chair of the Board.
Effective as of the Transition Date, the Board appointed Ian F. Smith, 59, a director on the Board, to succeed Dr. Kaye as Interim Chief Executive Officer (“Interim CEO”).
Lara S. Sullivan, M.D., President and Chief Executive Officer will assume the role of Chief Medical Officer along with her current role as President and Chief Executive Officer.
On March 18, 2025, the Company announced that Ken Kobayashi, M.D., F.A.C.P, is stepping down from his position as the Company's Chief Medical Officer.
On March 13, 2025, the Board of Directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”) appointed Ian Hodgson as Chief Operating Officer effective March 15, 2025.
On March 12, 2025, Michael Crawford informed the Board of Directors of Hall of Fame Resort & Entertainment Company (the “Company”) that he intends to resign as President, Chief Executive Officer, and Chairman of the Board of Directors.
Effective as of the Transition Date, the Company has appointed Viktoryia G. Pulliam as the Company’s Senior Vice President and Chief Accounting Officer.
On March 14, 2025, Mr. Thomas E. Haas, age 64, who has served as Golden Entertainment, Inc.’s (the “Company”) Senior Vice President and Chief Accounting Officer since March 2020, informed the Company of his decision to retire effective March 21, 2025 (the “Transition Date”).
Additionally, on March 18, 2024, the Company announced that the Chief Operations Officer position is being eliminated and as a result, Melody Harris, the current Chief Operations Officer, will no longer hold such role and will no longer be a named executive officer effective April 1, 2025.
On March 18, 2025, NeoGenomics, Inc. (the "Company") announced the promotion of Warren Stone, the Company's current Chief Commercial Officer, to the position of President & Chief Operating Officer, effective April 1, 2025.
On March 18, 2025, Cummins Inc. (the “Company”) issued a press release announcing that Sharon R. Barner, the Company’s Chief Administrative Officer, will retire from the Company, effective May 31, 2025.
Mr. Duvall will remain with the Company as an employee and on the Effective Date, will serve as Global Corporate Controller for the Company.
On February 27, 2025, NCR Atleos Corporation (the “Company”) entered into an offer letter which appointed Traci Hornfeck as its Senior Vice President and Chief Accounting Officer, effective as of March 31, 2025
E. Forrest Jones, Jr. resigned from the Board of Directors (the “Board”) and from his positions on all committees of the Board effective March 14, 2025.
the Board appointed E. Forrest Jones, Jr. as the Company’s new General Counsel effective on or about May 1, 2025
the Board approved the appointment of the Company’s current General Counsel and Secretary, Evan H. Jenkins, age 64, to serve as a member of the Board filling the vacancy left by Mr. Jones’ resignation. The Board also approved the appointment of Mr. Jenkins as Vice-Chairman of the Board.
the Board appointed as a director of the Company General John M. “Jack” Keane (Ret.), effective immediately
Trisha Gosser has been appointed as the Chief Financial Officer of Gannett Co., Inc. (the “Company”).
The Board of Directors (the “Board”) of ACM Research, Inc. (the “Company”) has appointed Charles Pappis to serve as a member of the Board and its Audit Committee, effective March 15, 2025.
appointed (i) Mr. Krishna Shivram to the Board as a Class I director and (ii) Mr. Vasudevan (Vasu) Guruswamy to the Board as a Class III director, both effective March 17, 2025.
appointed (i) Mr. Krishna Shivram to the Board as a Class I director and (ii) Mr. Vasudevan (Vasu) Guruswamy to the Board as a Class III director, both effective March 17, 2025.
Gina Chapman, the Company’s President, CEO and member of the board of directors will be leaving the Company effective May 19, 2025.
Dr. Ginna Laport, the Company’s Chief Medical Officer ("CMO"), will be leaving the Company effective May 19, 2025.
the Board appointed Anup Radhakrishnan, the Company’s Chief Financial Officer and Chief Operating Officer, to succeed Ms. Chapman as interim CEO.
On March 12, 2025, Eric K. Brandt advised the Board of Directors (the “Board”) of The Macerich Company (the “Company”) that he will not stand for re-election as a director of the Company at the 2025 annual meeting of stockholders (the “2025 Annual Meeting”).
On March 12, 2025, Jaynie Studenmund, a member of the Board of Directors (the “Board”) of ExlService Holdings, Inc. (the “Company”), notified the Board that she has decided not to stand for re-election at the Company’s 2025 annual meeting of stockholders (the “Annual Meeting”), at which time she will resign from the Board and the committees on which she currently serves.
at the Effective Time, Vikas Sinha, Derek Adams, Ph.D., Malcom Brenner, M.D., Ph.D., Jeffrey S. Bornstein, Shawn Tomasello and Juan Vera, M.D., resigned from the Board
the Board was reconstituted as follows: (i) David Hallal and Morana Jovan-Embiricos, Ph.D. (designated by AlloVir), (ii) Andrew Oxtoby, Anthony Adamis, Srinivas Akkaraju, M.D., Ph.D., Michael Dybbs, Ph.D., Napoleone Ferrara, M.D., and Samir Patel, M.D.
the Board was reconstituted as follows: (i) David Hallal and Morana Jovan-Embiricos, Ph.D. (designated by AlloVir), (ii) Andrew Oxtoby, Anthony Adamis, Srinivas Akkaraju, M.D., Ph.D., Michael Dybbs, Ph.D., Napoleone Ferrara, M.D., and Samir Patel, M.D.
David Hallal was appointed Chair of the Board.
at the Effective Time, Vikas Sinha, Derek Adams, Ph.D., Malcom Brenner, M.D., Ph.D., Jeffrey S. Bornstein, Shawn Tomasello and Juan Vera, M.D., resigned from the Board
the Board was reconstituted as follows: (i) David Hallal and Morana Jovan-Embiricos, Ph.D. (designated by AlloVir), (ii) Andrew Oxtoby, Anthony Adamis, Srinivas Akkaraju, M.D., Ph.D., Michael Dybbs, Ph.D., Napoleone Ferrara, M.D., and Samir Patel, M.D.
at the Effective Time, Vikas Sinha, Derek Adams, Ph.D., Malcom Brenner, M.D., Ph.D., Jeffrey S. Bornstein, Shawn Tomasello and Juan Vera, M.D., resigned from the Board
at the Effective Time, Vikas Sinha, Derek Adams, Ph.D., Malcom Brenner, M.D., Ph.D., Jeffrey S. Bornstein, Shawn Tomasello and Juan Vera, M.D., resigned from the Board
at the Effective Time, Vikas Sinha, Derek Adams, Ph.D., Malcom Brenner, M.D., Ph.D., Jeffrey S. Bornstein, Shawn Tomasello and Juan Vera, M.D., resigned from the Board
the Board was reconstituted as follows: (i) David Hallal and Morana Jovan-Embiricos, Ph.D. (designated by AlloVir), (ii) Andrew Oxtoby, Anthony Adamis, Srinivas Akkaraju, M.D., Ph.D., Michael Dybbs, Ph.D., Napoleone Ferrara, M.D., and Samir Patel, M.D.
the Board was reconstituted as follows: (i) David Hallal and Morana Jovan-Embiricos, Ph.D. (designated by AlloVir), (ii) Andrew Oxtoby, Anthony Adamis, Srinivas Akkaraju, M.D., Ph.D., Michael Dybbs, Ph.D., Napoleone Ferrara, M.D., and Samir Patel, M.D.
at the Effective Time, Vikas Sinha, Derek Adams, Ph.D., Malcom Brenner, M.D., Ph.D., Jeffrey S. Bornstein, Shawn Tomasello and Juan Vera, M.D., resigned from the Board
the Board was reconstituted as follows: (i) David Hallal and Morana Jovan-Embiricos, Ph.D. (designated by AlloVir), (ii) Andrew Oxtoby, Anthony Adamis, Srinivas Akkaraju, M.D., Ph.D., Michael Dybbs, Ph.D., Napoleone Ferrara, M.D., and Samir Patel, M.D.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.